|Toxiciy Grade:||5||City/State/Province:||Boston, MA|
|Treatments:||Biologic therapy||Hospital:||Massachusetts General Hospital Cancer Center|
This phase 3 study involved 716 men with castration-resistant prostate cancer. The median patient age was 74 years.
Patients were treated with the biologic therapy agent denosumab, which is a monoclonal antibody that inactivates a protein called RANKL and subsequently works to prevent bone metastases commonly associated with prostate cancer.
Treatment-related deaths were reported, but specific causes were not given. Severe anemia, urinary tract infection, and loss of bone density were reported.
The reported median overall survival was 43.9 months.
This study was supported by Amgen, makers of denosumab.
Correspondence: Dr. Matthew R Smith; email: firstname.lastname@example.org